Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX – Get Free Report) shares shot up 2.1% on Wednesday. The stock traded as high as $0.7417 and last traded at $0.6851. Approximately 18,729 shares were traded during trading, a decline of 61% from the average daily volume of 48,471 shares. The stock had previously closed at $0.6710.
Wall Street Analyst Weigh In
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Radiopharm Theranostics in a research report on Thursday, October 15th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $11.00.
Read Our Latest Research Report on RADX
Radiopharm Theranostics Stock Down 6.3%
The company’s fifty day moving average price is $1.16 and its two-hundred day moving average price is $3.37.
Radiopharm Theranostics (NASDAQ:RADX – Get Free Report) last posted its quarterly earnings results on Friday, July 31st. The company reported ($0.81) earnings per share (EPS) for the quarter. The company had revenue of $0.49 million for the quarter. As a group, sell-side analysts expect that Radiopharm Theranostics Limited – Sponsored ADR will post -3.23 EPS for the current year.
Radiopharm Theranostics Company Profile
Radiopharm Theranostics is an Australian clinical-stage biotechnology company developing radiopharmaceuticals for cancer imaging and treatment. Its theranostic approach uses radioactive compounds designed to help identify cancer and, in some cases, deliver targeted radiation to tumors. The company’s research programs span several types of targeting agents, including peptides, small molecules, antibodies and nanobodies. Its pipeline includes candidates in development for imaging or treating cancers such as brain, breast and kidney cancer.
Recommended Stories
- Five stocks we like better than Radiopharm Theranostics
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Radiopharm Theranostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radiopharm Theranostics and related companies with MarketBeat.com's FREE daily email newsletter.
